2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…2020 American Transplant Congress
National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States
1Stanford University, Redwood City, CA, 2University of California, San Francisco, San Francisco, CA
*Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened…2020 American Transplant Congress
Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Yttrium-90 microspheres radioembolization (Y90) has shown to be effective as a bridging therapy for patients with advanced hepatocellular carcinoma (HCC) while on waiting list…2020 American Transplant Congress
Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant
*Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time…2020 American Transplant Congress
Imaging Features and Diagnostic Accuracy of MRI in Combined Hepatocholangiocarcinoma
*Purpose: Combined hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis after…2020 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL
*Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…2020 American Transplant Congress
Efficacy of Radiofrequency Ablation in the Treatment of Patients with Hepatocellular Carcinoma and Compensated Liver Disease: A Pathological Evaluation of Liver Explants
*Purpose: Radiofrequency ablation (RFA) is a safe and effective treatment for patients with limited hepatocellular carcinoma (HCC). Ablative outcomes have been largely based on radiological…2020 American Transplant Congress
Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) recurrence after transplantation is associated with higher tumor grade on explant, failure to respond to DEB-TACE, and pretreatment lymphopenia. We prospectively…2020 American Transplant Congress
Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation
1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Peritumoral neutrophil (PMN) infiltration has been associated with poor clinical outcomes in various tumors; however, its role in hepatocellular carcinoma (HCC) remains understudied. Moreover,…2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 23
- Next Page »